Immunotherapy for Inhalant Allergy
Introduction
Introduction
- Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
- Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
- Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
- Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.
Treatment
Treatmen...
...Abbreviations and Definitions of Common...
...ble 2. Summary of Guideline Key Action...
...sessment
...Candidacy for Allergen ImmunotherapyClinic...
...uld not get Allergen ImmunotherapyC...
...Who may not get Allergen ImmunotherapyClinic...
...ma AssessmentClinicians should evaluate the pati...
...ducation...
...regarding SLIT versus SCITClinicians s...
...ion regarding Preventive Qualities of Alle...
...atment...
...Seasonal TherapyClinicians who administer...
...Selecting Clinically Relevant Allergens...
...ting Polysensitized Patients with Limi...
...tions and Allergen Immunotherapy Esca...
...Identification and ManagementThe clinician perfo...
...During Allergen ImmunotherapyClinicians should av...
...2. Duration for Allergen Immunotherapy...
...able 3: Comparison of SCIT and SLIT M...
...rld Allergy Organization Subcutaneous Immunoth...
...e 1. Pre-/Co-Seasonal SLIT Time CourseTi...
...phylaxis Diagnostic Criteria Reprod...
...ntiating Between Vasovagal and Anaph...
...ment of AnaphylaxisReproduced from the World Al...
...re 4. Flowchart Showing Key Action Statements...